Serum angiotensin-converting enzyme levels in patients with recent- onset insulin-dependent diabetes after one year of low-dose cyclosporin therapy

C. Letizia, C. D'Ambrosio, A. De Ciocchis, D. Scavo, P. Pozzilli, N. Visalli, M. A. Mesturino, M. L. Bocconi, E. Fionti, A. Signore, R. Buzzetti, G. Cavallo, G. De Mattia, M. C. Faldetta, G. Multari, L. Campea, M. A. Suppa, L. Lucentini, A. Crino

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cyclosporin A (CyA) is today used for the treatment of autoimmune diseases and in the past was given also to patients with recent-onset insulin-dependent diabetes mellitus (IDDM). Hypertension is a major hazard in patients receiving CyA. In this study we have evaluated the effect of CyA administered to IDDM patients on blood pressure and serum angiotensin- converting enzyme (SACE), an endopeptidase that is an integral part of the renin-angiotensin and bradykinin systems. Sera from patients affected by recent-onset IDDM who were treated with CyA at the dose of 5 mg/kg body weight in addition to insulin therapy were included in the study (n = 13. Sera from 9 IDDM patients with the same clinical characteristics and followed up for 12 months represented the control group (insulin therapy only). SACE levels were measured at diagnosis and after 12 months. The results showed that SACE levels were elevated in IDDM patients at diagnosis and remained significantly high at 12 months in CyA-treated patients as compared to control patients (p <0.006). Systolic and diastolic blood pressure were increased at 12 months in CyA-treated patients (p <0.005 and p <0.05, respectively). CyA therapy administered even at low doses to IDDM patients may increase SACE levels and also blood pressure. These findings should be considered when CyA is used for therapy of autoimmune diseases.

Original languageEnglish
Pages (from-to)209-213
Number of pages5
JournalInternational Journal of Clinical Pharmacology Research
Volume15
Issue number5-6
Publication statusPublished - 1995

Fingerprint

Peptidyl-Dipeptidase A
Cyclosporine
Insulin
Type 1 Diabetes Mellitus
Serum
Blood Pressure
Therapeutics
Autoimmune Diseases
Endopeptidases
Bradykinin
Renin-Angiotensin System
Group Psychotherapy
Body Weight
Hypertension
Control Groups

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Serum angiotensin-converting enzyme levels in patients with recent- onset insulin-dependent diabetes after one year of low-dose cyclosporin therapy. / Letizia, C.; D'Ambrosio, C.; De Ciocchis, A.; Scavo, D.; Pozzilli, P.; Visalli, N.; Mesturino, M. A.; Bocconi, M. L.; Fionti, E.; Signore, A.; Buzzetti, R.; Cavallo, G.; De Mattia, G.; Faldetta, M. C.; Multari, G.; Campea, L.; Suppa, M. A.; Lucentini, L.; Crino, A.

In: International Journal of Clinical Pharmacology Research, Vol. 15, No. 5-6, 1995, p. 209-213.

Research output: Contribution to journalArticle

Letizia, C, D'Ambrosio, C, De Ciocchis, A, Scavo, D, Pozzilli, P, Visalli, N, Mesturino, MA, Bocconi, ML, Fionti, E, Signore, A, Buzzetti, R, Cavallo, G, De Mattia, G, Faldetta, MC, Multari, G, Campea, L, Suppa, MA, Lucentini, L & Crino, A 1995, 'Serum angiotensin-converting enzyme levels in patients with recent- onset insulin-dependent diabetes after one year of low-dose cyclosporin therapy', International Journal of Clinical Pharmacology Research, vol. 15, no. 5-6, pp. 209-213.
Letizia, C. ; D'Ambrosio, C. ; De Ciocchis, A. ; Scavo, D. ; Pozzilli, P. ; Visalli, N. ; Mesturino, M. A. ; Bocconi, M. L. ; Fionti, E. ; Signore, A. ; Buzzetti, R. ; Cavallo, G. ; De Mattia, G. ; Faldetta, M. C. ; Multari, G. ; Campea, L. ; Suppa, M. A. ; Lucentini, L. ; Crino, A. / Serum angiotensin-converting enzyme levels in patients with recent- onset insulin-dependent diabetes after one year of low-dose cyclosporin therapy. In: International Journal of Clinical Pharmacology Research. 1995 ; Vol. 15, No. 5-6. pp. 209-213.
@article{6910c1629977464ebc6d726f13555cc1,
title = "Serum angiotensin-converting enzyme levels in patients with recent- onset insulin-dependent diabetes after one year of low-dose cyclosporin therapy",
abstract = "Cyclosporin A (CyA) is today used for the treatment of autoimmune diseases and in the past was given also to patients with recent-onset insulin-dependent diabetes mellitus (IDDM). Hypertension is a major hazard in patients receiving CyA. In this study we have evaluated the effect of CyA administered to IDDM patients on blood pressure and serum angiotensin- converting enzyme (SACE), an endopeptidase that is an integral part of the renin-angiotensin and bradykinin systems. Sera from patients affected by recent-onset IDDM who were treated with CyA at the dose of 5 mg/kg body weight in addition to insulin therapy were included in the study (n = 13. Sera from 9 IDDM patients with the same clinical characteristics and followed up for 12 months represented the control group (insulin therapy only). SACE levels were measured at diagnosis and after 12 months. The results showed that SACE levels were elevated in IDDM patients at diagnosis and remained significantly high at 12 months in CyA-treated patients as compared to control patients (p <0.006). Systolic and diastolic blood pressure were increased at 12 months in CyA-treated patients (p <0.005 and p <0.05, respectively). CyA therapy administered even at low doses to IDDM patients may increase SACE levels and also blood pressure. These findings should be considered when CyA is used for therapy of autoimmune diseases.",
author = "C. Letizia and C. D'Ambrosio and {De Ciocchis}, A. and D. Scavo and P. Pozzilli and N. Visalli and Mesturino, {M. A.} and Bocconi, {M. L.} and E. Fionti and A. Signore and R. Buzzetti and G. Cavallo and {De Mattia}, G. and Faldetta, {M. C.} and G. Multari and L. Campea and Suppa, {M. A.} and L. Lucentini and A. Crino",
year = "1995",
language = "English",
volume = "15",
pages = "209--213",
journal = "International Journal of Clinical Pharmacology Research",
issn = "0251-1649",
publisher = "Bioscience Ediprint Inc.",
number = "5-6",

}

TY - JOUR

T1 - Serum angiotensin-converting enzyme levels in patients with recent- onset insulin-dependent diabetes after one year of low-dose cyclosporin therapy

AU - Letizia, C.

AU - D'Ambrosio, C.

AU - De Ciocchis, A.

AU - Scavo, D.

AU - Pozzilli, P.

AU - Visalli, N.

AU - Mesturino, M. A.

AU - Bocconi, M. L.

AU - Fionti, E.

AU - Signore, A.

AU - Buzzetti, R.

AU - Cavallo, G.

AU - De Mattia, G.

AU - Faldetta, M. C.

AU - Multari, G.

AU - Campea, L.

AU - Suppa, M. A.

AU - Lucentini, L.

AU - Crino, A.

PY - 1995

Y1 - 1995

N2 - Cyclosporin A (CyA) is today used for the treatment of autoimmune diseases and in the past was given also to patients with recent-onset insulin-dependent diabetes mellitus (IDDM). Hypertension is a major hazard in patients receiving CyA. In this study we have evaluated the effect of CyA administered to IDDM patients on blood pressure and serum angiotensin- converting enzyme (SACE), an endopeptidase that is an integral part of the renin-angiotensin and bradykinin systems. Sera from patients affected by recent-onset IDDM who were treated with CyA at the dose of 5 mg/kg body weight in addition to insulin therapy were included in the study (n = 13. Sera from 9 IDDM patients with the same clinical characteristics and followed up for 12 months represented the control group (insulin therapy only). SACE levels were measured at diagnosis and after 12 months. The results showed that SACE levels were elevated in IDDM patients at diagnosis and remained significantly high at 12 months in CyA-treated patients as compared to control patients (p <0.006). Systolic and diastolic blood pressure were increased at 12 months in CyA-treated patients (p <0.005 and p <0.05, respectively). CyA therapy administered even at low doses to IDDM patients may increase SACE levels and also blood pressure. These findings should be considered when CyA is used for therapy of autoimmune diseases.

AB - Cyclosporin A (CyA) is today used for the treatment of autoimmune diseases and in the past was given also to patients with recent-onset insulin-dependent diabetes mellitus (IDDM). Hypertension is a major hazard in patients receiving CyA. In this study we have evaluated the effect of CyA administered to IDDM patients on blood pressure and serum angiotensin- converting enzyme (SACE), an endopeptidase that is an integral part of the renin-angiotensin and bradykinin systems. Sera from patients affected by recent-onset IDDM who were treated with CyA at the dose of 5 mg/kg body weight in addition to insulin therapy were included in the study (n = 13. Sera from 9 IDDM patients with the same clinical characteristics and followed up for 12 months represented the control group (insulin therapy only). SACE levels were measured at diagnosis and after 12 months. The results showed that SACE levels were elevated in IDDM patients at diagnosis and remained significantly high at 12 months in CyA-treated patients as compared to control patients (p <0.006). Systolic and diastolic blood pressure were increased at 12 months in CyA-treated patients (p <0.005 and p <0.05, respectively). CyA therapy administered even at low doses to IDDM patients may increase SACE levels and also blood pressure. These findings should be considered when CyA is used for therapy of autoimmune diseases.

UR - http://www.scopus.com/inward/record.url?scp=0029547412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029547412&partnerID=8YFLogxK

M3 - Article

C2 - 8835619

AN - SCOPUS:0029547412

VL - 15

SP - 209

EP - 213

JO - International Journal of Clinical Pharmacology Research

JF - International Journal of Clinical Pharmacology Research

SN - 0251-1649

IS - 5-6

ER -